| REVIEW ARTICLE |
|
| Year : 2020 | Volume
: 6
| Issue : 1 | Page : 5-12 |
|
|
Rituximab in dermatology: Revisited
Aditya Kumar Bubna
Department of Dermatology, IQ City Medical College, Sovapur, Jemua, Durgapur, West Bengal, India
Correspondence Address:
Dr. Aditya Kumar Bubna
Department of Dermatology, IQ City Medical College, Sovapur, Bijra Road, Jemua, Durgapur - 713 206, West Bengal
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijdd.ijdd_9_19
|
|
|
Rituximab (RTX) is a specific mouse and human chimeric monoclonal antibody that has found to have numerous applications in dermatology. Though initially approved by the US FDA for treating rheumatoid arthritis and non-Hodgkin's lymphoma; currently its approval has extended to involve the pemphigus group of disorders; both as a first line drug as well as a therapeutic strategy for recalcitrant cases of pemphigus, unresponsive to conventional therapy. Apart from pemphigus, there have been a number of cutaneous disorders where rituximab has been found to be useful. This review will give a bird's eye view of the applications of rituximab in dermatology.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
